Frederique Vegran

List of Publications by Year
in descending order

62	5,853	172457	138484
papers	citations	29 h-index	58 g-index

67	67	67	10300
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of T_H1 and T_H9 cells. , 2022, 10, e003459.		21
2	Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses. Nature Immunology, 2022, 23, 262-274.	14.5	47
3	Alternative Splicing in Cancer and Immune Cells. Cancers, 2022, 14, 1726.	3.7	15
4	Impact of Lipid Metabolism on Antitumor Immune Response. Cancers, 2022, 14, 1850.	3.7	18
5	Protein Kinase Inhibitor-Mediated Immunoprophylactic and Immunotherapeutic Control of Colon Cancer. Frontiers in Immunology, 2022, 13, 875764.	4.8	2
6	Role of Cytokines and Chemokines in Angiogenesis in a Tumor Context. Cancers, 2022, 14, 2446.	3.7	32
7	<scp>NLRP6</scp> negatively regulates type 2 immune responses in mice. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3320-3336.	5.7	4
8	Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects. Cancer Immunology Research, 2022, 10, 900-916.	3.4	2
9	The Tumor Microenvironment Impairs Th1 IFNÎ³ Secretion through Alternative Splicing Modifications of Irf1 Pre-mRNA. Cancer Immunology Research, 2021, 9, 324-336.	3.4	8
10	Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment. Cancers, 2021, 13, 373.	3.7	18
11	Cleaved Caspase-3 Transcriptionally Regulates Angiogenesis-Promoting Chemotherapy Resistance. Cancer Research, 2019, 79, 5958-5970.	0.9	55
12	Regulation of T cell antitumor immune response by tumor induced metabolic stress. Cell Stress, 2019, 3, 9-18.	3.2	14
13	PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer. OncoImmunology, 2018, 7, e1433981.	4.6	167
14	Transcriptional Programs Underlying Cd4 T Cell Differentiation and Functions. International Review of Cell and Molecular Biology, 2018, 341, 1-61.	3.2	12
15	Transcription Factor Binding Studies in CD4+ T Cells: siRNA Transfection, Chromatin Immunoprecipitation, and Liquid Luminescent DNA Precipitation Assay. Methods in Molecular Biology, 2017, 1585, 167-177.	0.9	0
16	O28 Importance of pro-inflammatory immune lymphocyte Th17 in antitumoral properties of resveratrol, a polyphenol of wine. Biochemical Pharmacology, 2017, 139, 118-119.	4.4	0
17	IRF8-dependent molecular complexes control the Th9 transcriptional program. Nature Communications, 2017, 8, 2085.	12.8	43
18	TH9 cells in anti-tumor immunity. Seminars in Immunopathology, 2017, 39, 39-46.	6.1	63

#	Article	IF	Citations
19	The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?. Oncotarget, 2017, 8, 1957-1971.	1.8	38
20	Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOXâ€“Bevacizumab Drug Treatment Regimen. Cancer Research, 2016, 76, 5241-5252.	0.9	203
21	Human ectonucleotidase-expressing CD25^{high}Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions. OncoImmunology, 2016, 5, e1055444.	4.6	39
22	Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein. World Journal of Gastroenterology, 2016, 22, 10680.	3.3	15
23	Liquid Luminescent DNA-precipitation Assay. Bio-protocol, 2016, 6, .	0.4	0
24	Proximity Ligation Assay (PLA) Protocol Using Duolink® for T Cells. Bio-protocol, 2016, 6, .	0.4	1
25	The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?. Journal of Clinical Oncology, 2016, 34, e13116-e13116.	1.6	1
26	Transcriptome analysis of TH2 CD4+ T cells differentiated from wild-type and NLRP3KO mice. Genomics Data, 2015, 5, 314-315.	1.3	10
27	Transcriptional expression of 8 genes predicts pathological response to first-line docetaxelâ€‰+â€‰trastuzumab-based neoadjuvant chemotherapy. BMC Cancer, 2015, 15, 169.	2.6	5
28	Th9 Cells: A Novel CD4 T-cell Subset in the Immune War against Cancer. Cancer Research, 2015, 75, 475-479.	0.9	56
29	The receptor NLRP3 is a transcriptional regulator of TH2 differentiation. Nature Immunology, 2015, 16, 859-870.	14.5	312
30	Liver X receptor Î² activation induces pyroptosis of human and murine colon cancer cells. Cell Death and Differentiation, 2014, 21, 1914-1924.	11.2	127
31	The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. Nature Immunology, 2014, 15, 758-766.	14.5	187
32	Transcriptional regulation of the survivin gene. Molecular Biology Reports, 2014, 41, 233-240.	2.3	59
33	Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nature Medicine, 2013, 19, 57-64.	30.7	634
34	Dacarbazine-Mediated Upregulation of NKG2D Ligands on Tumor Cells Activates NK and CD8 T Cells and Restrains Melanoma Growth. Journal of Investigative Dermatology, 2013, 133, 499-508.	0.7	75
35	SOCS3 Transactivation by PPARÎ³ Prevents IL-17â€“Driven Cancer Growth. Cancer Research, 2013, 73, 3578-3590.	0.9	51
36	Survivin-3B Potentiates Immune Escape in Cancer but Also Inhibits the Toxicity of Cancer Chemotherapy. Cancer Research, 2013, 73, 5391-5401.	0.9	23

#	Article	IF	Citations
37	Survivin-3B promotes chemoresistance and immune escape by inhibiting caspase-8 and -6 in cancer cells. OncoImmunology, 2013, 2, e26328.	4.6	10
38	STAT3 activation. Jak-stat, 2013, 2, e23010.	2.2	159
39	Socs3 induction by PPARÎ³ restrains cancer-promoting inflammation. Cell Cycle, 2013, 12, 2157-2158.	2.6	8
40	Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells. PLoS ONE, 2013, 8, e65181.	2.5	103
41	Only Missense Mutations Affecting the DNA Binding Domain of P53 Influence Outcomes in Patients with Breast Carcinoma. PLoS ONE, 2013, 8, e55103.	2.5	36
42	Role of IL-17 and IL-17 Family Cytokines on Tumor Development. , 2013, , 219-230.		0
43	Regulation of Monocarboxylate Transporter MCT1 Expression by p53 Mediates Inward and Outward Lactate Fluxes in Tumors. Cancer Research, 2012, 72, 939-948.	0.9	172
44	Lactate-Induced IL-8 Pathway in Endothelial Cellsâ€"Response: Figure 1.. Cancer Research, 2012, 72, 1903-1904.	0.9	6
45	Stat3 and Gfi-1 Transcription Factors Control Th17 Cell Immunosuppressive Activity via the Regulation of Ectonucleotidase Expression. Immunity, 2012, 36, 362-373.	14.3	275
46	Targeting the Lactate Transporter MCT1 in Endothelial Cells Inhibits Lactate-Induced HIF-1 Activation and Tumor Angiogenesis. PLoS ONE, 2012, 7, e33418.	2.5	412
47	A Short Caspase-3 Isoform Inhibits Chemotherapy-Induced Apoptosis by Blocking Apoptosome Assembly. PLoS ONE, 2011, 6, e29058.	2.5	33
48	Restoration of Antitumor Immunity Through Selective Inhibition of Myeloid Derived Suppressor Cells by Anticancer Therapies. Current Molecular Medicine, 2011, 11, 365-372.	1.3	64
49	Apoptosis gene signature of Survivin and its splice variant expression in breast carcinoma. Endocrine-Related Cancer, 2011, 18, 783-792.	3.1	26
50	Lactate Influx through the Endothelial Cell Monocarboxylate Transporter MCT1 Supports an NF-Î°B/IL-8 Pathway that Drives Tumor Angiogenesis. Cancer Research, 2011, 71, 2550-2560.	0.9	637
51	The transcription factor GATA-1 is overexpressed in breast carcinomas and contributes to survivin upregulation via a promoter polymorphism. Oncogene, 2010, 29, 2577-2584.	5.9	42
52	Gene expression profile and response to trastuzumabâ€"docetaxel-based treatment in breast carcinoma. British Journal of Cancer, 2009, 101, 1357-1364.	6.4	27
53	Variations in Gene Expression and Response to Neoadjuvant Chemotherapy in Breast Carcinoma. Cancer Investigation, 2009, 27, 521-528.	1.3	6
54	Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy. International Journal of Molecular Medicine, 2009, 23, 285-91.	4.0	22

#	Article	IF	Citations
55	The expression of BIRC5 is correlated with loss of specific chromosomal regions in breast carcinomas. Genes Chromosomes and Cancer, 2008, 47, 299-308.	2.8	40
56	Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. Journal of Clinical Investigation, 2008, 118, 3930-42.	8.2	1,225
57	Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene, 2007, 26, 290-297.	5.9	60
58	Overexpression of Caspase-3s Splice Variant in Locally Advanced Breast Carcinoma Is Associated with Poor Response to Neoadjuvant Chemotherapy. Clinical Cancer Research, 2006, 12, 5794-5800.	7.0	67
59	Distinct expression of Survivin splice variants in breast carcinomas. International Journal of Oncology, 2005, 27, 1151.	3.3	13
60	Distinct expression of Survivin splice variants in breast carcinomas. International Journal of Oncology, 2005, 27, 1151-7.	3.3	18
61	Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy. International Journal of Molecular Medicine, 1998, 23, 285.	4.0	12
62	Patterns of loss of heterozygosity in breast carcinoma during neoadjuvant chemotherapy. International Journal of Oncology, 0, , .	3.3	5